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INTRODUCTION
Study of the cell proliferative state has yielded information
concerning the proliferative activities of malignant tumors
which contribute to the understanding the biological
behavior of cancer. Examination of tritiated thymidine in
vivo or in vitro and bromodeoxyuridine [BUdR] labeling
index of the proliferative state of tumor cells in gastric
carcinomas and breast carcinomas was believed to be
meaningful in judging prognosis of cancer (1, 2, 3).
Yonemura et al. (4) reported that tumors having a high
Ki-67 labeling rate had a high frequency of vessel
invasion, with consequent poor prognosis and survival.
Proliferative cell nuclear antigen (PCNA/cyclin) is a 36KD
acidic nuclear protein associated with cell proliferation
and expressed mainly, but not absolutely, in the cell
nuclus (5).
Compared with BUdR, although the mechanism is
almost identical, examination of PCNA is more convenient
and can be used on archival specimens. Many studies of
PCNA in different tumors have been carried out, but the
conclusions are inconsistent (6, 7, 8, 9). Some authors
believe that PCNA is a valid marker of proliferation in
gastric and other tumors and may be a significant
prognostic indicator (10, 11). Tumors with high proliferative
activity show a more malignant clinical course and poorer
prognosis than those with low proliferative activity (2).
Other authors believed that there remain some doubts as
to the relationship between PCNA expression and cell
proliferation in the context of at least some forms
of neoplasia (12). Thus the significance of PCNA
immunoreactivity in tumors has yet to be fully established
(13). Moreover, few papers have studied the relationship
of PCNA expression between biopsy and autopsy in the
same patient. We examined and compared PCNA
expression in biopsy and autopsy to determine whether
the proliferative activity of both specimens determined by
PC10, a mouse monoclonal antibody to PCNA, would
provide useful and reliable information for the clinical
outcomes of patients with gastric cancer. Also we wanted
to clarify the differences in biological activity between
longer and shorter survival cases in addition to the
relation to sex and age.
MATERIALS AND METHODS
Fifty-eight autopsy specimens and 24 biopsy specimens
of gastric cancers were chosen from the files of
Tokushima University Hospital, Japan, from 1968 to 1989
without any bias. The diagnosis was confirmed by
histological examination and pathological criteria. The
ages of patients ranged from 27 to 88 years old (mean, 63
years old), male 38, female 20. Of the biopsy specimens
11 out of 24 died of cancer including 2 who died of
cancer bleeding. Of the autopsy specimens, 33 out of 58
underwent surgery and had recurrence. Both biopsy and
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autopsy specimens were available for study in 24 of the
58 patients. All sections were cut from formalin-fixed,
paraffin-embedded blocks. Anti-PCNA monoclonal antibody
PC 10 from Dakopatts (Copenhagen, Denmark) was used.
Immunostaining
Immunostaining was performed on the sections using
the Avidin-Biotin-Peroxidase complex (ABC) technique.
After deparaffinization by incubation at 60℃ for 30
minutes and dehydration in a graded ethanol series, the
sections were incubated sequentially with the following
solutions : 1. 0.3% hydrogen peroxide in absolute methanol
for 30 minutes to remove endogenous peroxidase activity ;
2. normal horse serum for 30 minutes to reduce
background staining ; 3. PC10 dilution of 1 : 100 with
overnight incubation at 4℃ was found to be optimal ;
4. ABC complexes (Dakopatts) diluted 1 : 200 at room
temperature for 40 minutes. 5. 0.03% 3, 3-diaminobenzidine
tetrahydrochloride solution to which hydrogen peroxide
(0.02%) was added just before use. Between each step of
the immunostaining procedure the sections were washed
in phosphate buffered saline (PBS). The intensity of
positive nuclear reaction for PCNA varied from weak to
strong.
In order to know what relationship exists between
PCNA intensity and patients' prognosis, age and sex, we
counted the labeling index (LI) twice : firstly, the cells
with strong nuclear reaction were counted ; secondly, not
only the cells with strong but also weak nuclear reaction
were counted. Figure 1 shows PCNA staining in a gastric
tumor. Immunoreaction was observed as strong reaction
(long arrow) or weak reaction (short arrow). The LI of
the cells with a strong nuclear reaction was 26.0% and the
LI of both the cells with strong and weak reaction was
66.0% in this case. We used this standard to evaluate all
sections.
Tumors with positive cells for PCNA were regarded as
positive cases regardless of the number of positive cells.
In the labeling index the data were presented as mean
±SD which was statistically analyzed by Student's t test.
The frequency of positive cases was statistically analyzed
by the Mann-Whitney test.
RESULTS
Immunoreactivity was observed in nuclei with only
occasional cytoplasmic staining in both biopsy and
autopsy specimens of gastric cancer. Figure 2 shows
hematoxylin & eosin (A) and PCNA staining (B) in the
same part of a gastric tumor (biopsy specimen). Only
nuclear staining was counted as positive. The results of
immunostaining in biopsy and autopsy specimens of all
gastric tumors are shown in Table I. Of the biopsy
specimens, 21 out of 24 cases (87.5%) were PCNA
positive. The autopsy specimens of these 24 patients
showed the same PCNA-positive ratio (87.5%). Of the all
58 autopsy specimens, 52 (89.7%) had PCNA-positive
tumor cells. No significant difference of frequency of
PCNA positive cases between biopsy and autopsy
specimens was found. The LI ranged from 0% to 50%
(mean 14.6%) in biopsy specimens at first counting and
from 0% to 75% (mean 30.6%) at second counting ; The
LI ranged from 0% to 59.5% (mean 10.1%) in autopsy
specimens at first counting and from 0% to 87% (mean
33.4%) at second counting. In neither the first counting
nor the second counting was any significant difference in
Fig.1. Photomicrograph of gastric carcinoma
(autopsy specimen) stained with proliferating
cell nuclear antigen (PCNA) monoclonal
antibody PC10. Immunoreaction is observed
with strong (long arrow) and weak reaction
(short arrow). (original magnification x 231).
Fig.2. Photomicrograph of gastric carcinoma (biopsy specimen) stained with H &
E (A) and with proliferating cell nuclear antigen (PCNA) monoclonal antibody
PC10 (B). Only nuclear staining is regarded as a PCNA-positive reaction. (original
magnification x 231).
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LI between biopsy and autopsy found.
We checked the duration from patients
death to autopsy, which ranged from
30minutes to 12 hours, against PCNA
reaction. Figure 3 shows the relationship
between post-mortem delay and PCNA
reaction, from which we found PCNA
reaction of samples was not influenced
by shorter or longer duration.
Table II shows PCNA reaction in
groups of different survival condition,
sex and age. Examining the survival
period, the shortest period from
biopsy to death was one half month ;
the longest 9 years. The cases with
shorter survival period from biopsy
to death did not show higher
incidences of PCNA expression. In
the biopsy specimens, the frequencies
of PCNA positive cases in the shorter
and longer groups were 83.3%
(15/18) and 100% (6/6) and in the
autopsy specimens, the frequencies
of PCNA positive cases were 94.4%
(17/18) and 66.7%, respectively (4/6).
The LI of these two groups showed
no significant difference among autopsy
Table I. PCNA Expression in Biopsy and Autopsy specimens of Gastric cancer
No. of PCNA
cases Positive Cases (%)
Labeling Index (%)
Mean±SD
1 st 2 nd
Biopsy 24 21(87.5) 14.6±25.2 30.6±24.8
NS NS NS
Autopsy 58 52(89.7) 10.1±13.5 33.4±24.5
NS : No significant difference.
1 st : First counting ; 2 nd : Second counting.
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Fig.3. The relationship between duration to tissue fixation and PCNA reaction. ■ : first
counting and □ : second counting.
Table II. PCNA Expression in Different Survival Period, Sex and Age Groups
Case
PCNA
Positive Cases (%)
Labeling Index (%)
(Mean±SD)
No. Biopsy Autopsy Biopsy Autopsy
１st ２nd １st ２nd
Shorter 18 15/18(83.3) 17/18(94.4) 11.0±15.3 23.9±24.1 11.0±15.8 34.6±23.7
Group
(＜１２Mon.) NS NS * * NS NS
Longer 6 6/6(100) 4/6(66.7) 25.5±8.9 50.5±15.0 1.4±1.30 17.0±14.7
Group
(>12 Mon.)
Male 38 17/18(94.4) 36/38(94.7) 15.7±15.9 31.0±24.5 11.5±14.2 36.2±24.7
NS NS NS NS NS NS
Female 20 4/6(66.7) 16/20(80.0) 11.6±13.8 29.2±28.0 7.5±11.9 28.9±26.4
Younger 4 3/3(100) 4/4(100) 24.2±24.5 32.7±29.1 28.1±23.3 61.5±30.9
Group
(<35) NS NS NS NS * *
Older 54 18/21(85.7) 49/54(90.7) 13.3±13.7 30.3±25.0 8.8±11.8 31.0±23.3
Group
(>35)
* : p<0.05.
NS : No significant difference.
1 st : First counting ; 2 nd : Second counting.
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specimens at either the first or second counting, but the
difference in biopsy specimens was statistically significant.
Namely, LI was significantly higher in the longer survival
group than in the shorter group. In the different sex groups
we found no significant difference between the frequency
of PCNA positive cases or LI and sex. Between older
and younger groups, in autopsy specimens the LI was
significantly different both in first and second counting.
Namely, LI was significantly higher in the younger group
than that in the older group.
DISCUSSION
It is very important to look for a reliable method to
judge biological activity of tumors. The prognosis in
patients with gastric cancer has been thought to be
dependent on the stage of disease, which include gross
finding, nodal and organ metastasis, histologic type and
vessel invasion, etc. (14). But these parameters appear
less valuable in determining of prognosis, especially in the
early stages. Therefore we need to obtain information
about the level of tumor aggression.
Malignant tumors are in a highly proliferative state, and
examination of the proliferative activity of the tumor cell
has thus been believed to be a promising method for
predicting malignancy and prognosis (15, 16). Amadori et
al. (2) reported that in the study of proliferative activity of
primary gastric tumors using tritiated thymidine labeling
technique the survival rate (3 years) of patients with
tumors having a low labeling index was higher (50%) than
those with a high labeling index (13%). Several similar
results associated with gastric cancer as well as prostatic
cancer, breast cancer and astrocytic neoplasm have been
reported (11, 17, 18, 19). But Hall et al. thought that the
significance of PCNA immunoreactivity in tumors is at
present uncertain (13). PCNA immunostaining with PC10
from formalin-fixed, paraffin embedded prostatic cancers
has little prognostic value (20), and PCNA staining of
stored paraffin sections is of little prognostic value in
patients with gastric cancer (21). In our study, we
examined and compared both biopsy and autopsy
specimens of gastric tumors in 24 cases, and found that
the frequency of PCNA positive cases and PCNA-LI in
biopsy specimens did not significantly differ from that in
autopsy specimens. We therefore are of the opinion that
both frequency of PCNA positive cases and LI should be
considered in evaluating the meaning of PCNA. Our
present study showed 87.5% (21/24) of biopsy specimens
and 89.7% (52/58) of autopsy specimens to have a
PCNA-positive reaction. The reason why all malignant
tumor cells were negative for PCNA in some cases is not
clear. We supposed that the negative PCNA staining may
be the result of inactivity due to a post-mortem delay
before fixation, but our investigation showed this to be
unfounded. Hattori et al. (22) reported that the patients
with an index >12% (the mean of all of PCNA values) had
a worse prognosis than those with an index <12%, when
weakly PCNA-stained nuclei were excluded. In our study
we counted twice : first time only strong PCNA-stained
nuclei was counted and second time both strong and weak
PCNA-stained nuclei was counted. However the results of
this double counting did not show a similar relationship.
Moreover, in biopsy, the LI of PCNA was significantly
higher in the longer survival group than in the shorter
group at both the first and second countings. On the other
hand, the LI of autopsy specimens was significantly higher
in the younger group than in the older group at both
countings. These findings suggest that the intensity of
PCNA reaction is not so important in the judgment of
prognosis of tumor, and that the survival period of the
patients can not be predicted by the intensity of PCNA
reaction, LI or PCNA-positive cases. There was little
relationship between PCNA expression and survival
period, either in biopsy or autopsy. The duration from
biopsy to death ranged from one half month to 9 years.
According to some other reports, a strong PCNA reaction
means poor prognosis and short survival period in some
cancers ; and those carcinomas with good prognosis
usually demonstrate a weak reaction (14,15). The results
of our study differed from these conclusions. We could
not confirm any the rule that the prognosis of tumors
can be predicted by PCNA reaction, or that PCNA is a
reliable prognostic factor. Our results suggested that the
frequency of PCNA positive cases, LI and the intensity of
PCNA reaction are not directly related to the activity of
tumor growth. We can not say that examination of PCNA
is meaningless in the study of gastric tumors, but we think
that care is necessary when imposing clinical and
clinicopathological values on PCNA.
REFERENCES
1. Ohyama S, Yonemura Y, Miyazaki I : Prognostic value
of S-phase fraction and DNA ploidy studied with in
vivo administration of bromodeoxyuridine on human
gastric cancers. Cancer 65 : 116-21, 1990
2. Amadori D, Bonaguri C, Volpi A, Nanni O, Zoli W,
Lundi N, Amadori A, Magni E, Saragoni A : Cell
kinetics and prognosis in gastric cancer. Cancer. 71 :
1-4, 1993
3. Meyer JS, Friedman E, McCrate MM, Bauer WC :
Prediction of early course of breast carcinoma by
thymidine labeling. Cancer 51 : 1879-86, 1983
4. Yonemura Y, Ooyama S, Sugiyama K, Ninomiya I,
Kamata T, Yamaguchi A, Matsumoto H, Miyazaki I :
Growth fractions in gastric carcinomas determined
with monoclonal antibody Ki-67. Cancer 65 : 1130-4,
1990
5. Prelich G, Tan CK, Kostura M, Mathews MB, So AG,
Downey KM, Stillman B : Functional identity of pro-
liferating cell nuclear antigen and a DNA polymerase-
delta auxiliary protein. Nature 326 : 517-20, 1987
6. Zimmer C, Gottschalk J, Cervos NJ, Martin H, Beil
M, Jautzke G : Proliferating cell nuclear antigen (PCNA)
in atypical and malignant meningiomas. Pathol Res
Pract 188 : 951-8, 1992
7. Gasparini G, Meli S, Pozza F, Cazzavillan S, Bevilacqua
P : PC10 antibody to proliferating cell nuclear antigen
X. B. He et al. PCNA and Gastric Cancer１５２
(PCNA) is not related to prognosis in human breast
carcinoma. Growth Regul 2 : 145-50, 1992
8. Frankenthaler RA, El-Naggar AK,OrdonezNG,Miller TS,
Batsakis JG : High correlation with survival of proliferating
cell nuclear antigen expression in mucoepidermoid
carcinoma of the parotid gland. Otolaryngol Head
Neck Surg 111 : 460-6, 1994
9. Sawada M, Ueda G, Inoue M, Shimizu H, Ogawa H,
Nakazawa A, Fujita M, Tanizawa O, Tsujimoto M :
Immunohistochemical study of proliferating cell nuclear
antigen (PCNA) in gynecological tumors and their
related lesions. Acta Obst Gynaec Jpn 44 : 181-7, 1992
10. Yu C, Hall PA, Fletcher CDM, Camplejohn R, Wasseem
N, Lane DP, Levison DP : Immuno-histochemical stai
ning with a monoclonal antibody to proliferating cell
nuclear antigen may be a good indicator of prognosis
in haemangiopericytomas (abstract). J Pathology161:
342 a, 1990
11. Yonemura Y, Kimura H, Fushida S, Tugawa K, Nakai
Y, Kaji M, Fonseca L, Yamaguchi A, Miyazaki I :
Analysis of proliferative activity using anti-proliferating
cell nuclear antigen antibody in gastric cancer tissue
specimens obtained by endoscopic biopsy. Cancer
71 : 2448-53, 1993
12. Hall PA, Levison DA, Woods AL. Yu CC-w, Kellock
DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn
R, Dover R, Waseem NH, Lane DP : Proliferating
cell nuclear antigen (PCNA) immunolocalization in
paraffin sections : an index of cell proliferation with
evidence of deregulated expression in some neoplasms.
J Pathol 162 : 285-94, 1990
13. Hall PA, Woods AL. Invited review : Immunohistochemical
markers of cellular proliferation : achievements, problems
and prospects. Cell Tissue Kinet 1990 ; 23 : 505-22.
14. Japanese Research Society for Gastric Cancer. The
general rules for the gastric cancer study in surgery
and pathology. Jpn J Surg 11 : 127-39, 1981
15. Schutte B, Reynders MMJ, Wiggers T, Arends JW,
Volovics L, Bosman FT, Blijham GH : Retrospective
analysis of the prognostic significance of DNA content
and proliferative activity in large bowel cancer. Cancer
Res 47 : 5494-6, 1987
16. Dreinhofer KE, Akerman M, Willen H, Anderson C,
Gustafson P, Rydholm A : Proliferating cell nuclear
antigen (PCNA) in high grade malignant fibrous
histocytoma : prognostic value in 48 patients. Int J
Cancer 59 : 379-82, 1994
17. Spires SE, Banks ER, Davey DD, Jennings CD,
Wood DP, Cibull ML : Proliferating cell nuclear antig
en in prostatic adenocarcinoma : correlation with
established prognostic indicators. Urology 43 : 660-6,
1994
18. Silvestrini R, Daidone BG, Gasparini G : Cell Kinetics
as a prognostic marker in node-negative breast cancer.
Cancer 56 : 1982-8, 1985
19. Haapasalo HK, Sallinen PK, Helen PT, Rantala IS, Helin
HJ, Isola JJ : Comparison of three quantitamethods
for PCNA immunostaining : appli-cability and relation
to survival in 83 astrocytic neoplasms. J Pathol 171 :
207-14, 1993
20. Visakorpi T:Proliferative Activity Determined by DNA
flow cytometry and proliferating cell nuclear antigen
(PCNA) immunohistochemistry as a prognostic factor
in prostatic carcinoma. J Pathol 168 : 7-13, 1992
21. Mangham DC, Rowlands DC, Newbold KM, Reynolds
GM, Fielding JWL, Hallissey MT : Expression of
proliferating cell nuclear antigen (PCNA) in gastric
carcinoma : no evidence for prognostic value. J Clin
Pathol 47 : 473-4, 1994
22. Hattori K, Uchida K, Akaza H, Koiso K, Nemoto R,
Harada M : Proliferating cell nuclear antigen cyclin in
human transitional cell carcinoma. Br J Urol 75 : 162-
6, 1995
１５３The Journal of Medical Investigation Vol.44 1998
